Wound Management News

Scarring can have a negative impact on patients’ quality of life, according to research presented by Joseph F. Sobanko, MD, FAAD, at the American Academy of Dermatology Summer Meeting in Boston.

Study results finding that Kybella demonstrated efficacy in treating submental fat, and may be an alternative to surgical treatment, was among the most-read articles of the past week on Healio.com/Dermatology.

Research finding that facial compression during sleep results in wrinkles, and possibly contributes to skin expansion, was among the most-read articles of the past week on Healio.com/Dermatology.

DermTech, a commercial stage molecular dermatology company developing non-invasive genes expression tests for clinical diagnosis in skin cancer and inflammatory skin conditions, announced that it has added Matthew Posard to its board of directors.

The FDA and Teva Pharmaceuticals announced that Teva has voluntarily suspended sales, marketing and distribution of the Zecuity patch.

Most surveyed dermatology patients preferred professional attire, including a white coat, for their dermatologists across treatment settings, according to study results recently published in JAMA Dermatology.

The FDA announced its investigation of the risk for serious burns and potential permanent scarring with the use of the Zecuity patch for treating migraines.

BALTIMORE — The investigational herpes simplex virus-2 vaccine GEN-003 was well-tolerated and reduced viral shedding and genital lesions up to 1 year after vaccination, according to data presented at the Annual Conference on Vaccine Research.

Surveyed participants reported that they had a significantly better perception of the appearance of linear scars compared with zigzag scars in three separate facial locations, according to study results published in JAMA Facial Plastic Surgery.

Focus Diagnostics has recalled its laboratory examination kits for herpes simplex virus 1 and 2 and group A streptococcus infection due to inaccurate test results, according to a press release. The FDA identified the event as a class 1 recall, as use of the devices may result in serious injuries or death.